Lukasz Kwinta
Overview
Explore the profile of Lukasz Kwinta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
56
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kwinta L, Konopka K, Okon K, Lobacz M, Chlosta P, Dudek P, et al.
Cancers (Basel)
. 2025 Jan;
17(2).
PMID: 39858039
: Bladder cancer is a significant clinical problem with approximately 500,000 new cases worldwide annually. In approximately 25% of cases, disease is diagnosed at a stage of invasion of the...
2.
Potocki P, Wisniowski R, Haus D, Chowaniec Z, Kozaczka M, Kustra M, et al.
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686636
Anti-EGFR antibodies combined with chemotherapy doublets are a cornerstone of the upfront treatment of colorectal cancer. RAS and BRAF mutations are established negative predictive factors for such therapy. The primary...
3.
Potocki P, Wojcik P, Chmura L, Goc B, Fedewicz M, Bielanska Z, et al.
Int J Mol Sci
. 2023 May;
24(10).
PMID: 37240418
BRAF V600E and KRAS mutations that occur in colorectal cancer (CRC) define a subpopulation of patients with an inferior prognosis. Recently, the first BRAF V600E-targeting therapy has been approved and...
4.
Buda-Nowak A, Kwinta L, Potocki P, Michalowska-Kaczmarczyk A, Slowik A, Konopka K, et al.
J Clin Med
. 2023 Feb;
12(4).
PMID: 36835886
Background: Breast cancer, with 2.3 million new cases and 0.7 million deaths every year, represents a great medical challenge worldwide. These numbers confirm that approx. 30% of BC patients will...
5.
Wysocki P, Lobacz M, Potocki P, Kwinta L, Michalowska-Kaczmarczyk A, Slowik A, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831410
Patients with advanced ovarian cancer (OC) have a detrimental prognosis. The options for systemic treatment of advanced OC in later lines of treatment are limited by the availability of active...
6.
Konopka K, Fraczek P, Lubas M, Micek A, Kwinta L, Streb J, et al.
J Clin Med
. 2022 Mar;
11(5).
PMID: 35268305
Background: Interplay between non-specific inflammatory reaction and tumor microenvironment in gastric cancer (GC) can be measured indirectly by assessing fluctuations in concentration of platelets. Cytotoxic chemotherapy affects these morphotic elements...
7.
Konopka K, Micek A, Ochenduszko S, Streb J, Potocki P, Kwinta L, et al.
J Clin Med
. 2021 Sep;
10(17).
PMID: 34501353
Background: Chemotherapy is a cornerstone of treatment in advanced gastric cancer (GC) with a proven impact on overall survival, however, reliable predictive markers are missing. The role of various inflammatory...
8.
Kwiatkowska-Borowczyk E, Czerwinska P, Mackiewicz J, Gryska K, Kazimierczak U, Tomela K, et al.
Oncoimmunology
. 2018 Nov;
7(11):e1509821.
PMID: 30377573
Allogeneic whole cell gene modified therapeutic melanoma vaccine (AGI-101H) comprising of two melanoma cell lines transduced with cDNA encoding fusion protein composed of IL-6 linked with the soluble IL-6 receptor...
9.
Rutkowski P, Kozak K, Mackiewicz J, Krzemieniecki K, Nawrocki S, Wasilewska-Tesluk E, et al.
Contemp Oncol (Pozn)
. 2015 Nov;
19(4):280-3.
PMID: 26557775
Aim Of The Study: The BRAF inhibitor vemurafenib has improved progression-free survival and overall survival in patients with BRAFV600-mutation-positive metastatic melanoma. Here we present the results of an open-label safety...
10.
Wozniak S, Mackiewicz-Wysocka M, Krokowicz L, Kwinta L, Mackiewicz J
Oncol Res Treat
. 2015 Mar;
38(3):105-8.
PMID: 25792081
Background: Ipilimumab is a fully human monoclonal antibody (mAb) targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4). Ipilimumab is currently approved in the U.S. and Europe for the treatment of metastatic melanoma in...